BioSpace News Archive

Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 6, 2020 to report its first quarter 2020 financial results and provide a corporate update.

Medable, Inc. , the leading global platform for decentralized clinical trials, and AliveCor , the leader in AI-based, personal ECG technology, today announced a partnership to dramatically scale remote clinical trials by enabling in-home ECGs with AliveCor’s KardiaMobile6L, the world’s only FDA-cleared six-lead personal ECG. As

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program. The Company will investigate novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on the Company’s wholly-owned patent-p

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark Williams, Chief Science Officer of Algernon, will be making a presentation entitled “The Science of Ifenprodil” on a special BioPub webcast today April 29th, 2020 hosted by Dr. KSS, MD, PhD at Noon EDT. The Company invites intereste

Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir --

Quantzig, global data analytics and advisory firm, that delivers actionable analytics solutions presents a new case study series that focuses on how coronavirus is impacting businesses across geographies

ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.

Titan Medical Inc. announces that it has closed a US$1.5 million senior secured loan facility (“Loan Facility”) from a leading global medical technology company. The Loan Facility has an interest rate of 8% per annum

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201, an allogeneic natural killer (NK) cell medicine for the treatment of solid tumor cancers. “We have made significant progress in our HDNK (healthy-donor NK) cell medicine program, and we are excited to advance EDIT-201 into development for the treatment of solid tumors,” said Charles Albright, Ph.D

An oral dietary supplement designed to help skin fight photoaging from the inside out.